Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
2.90B | 2.89B | 2.95B | 2.89B | 2.83B | 2.15B | Gross Profit |
1.00B | 998.50M | 1.13B | 1.14B | 1.18B | 767.80M | EBIT |
558.70M | 569.90M | 676.00M | 734.00M | 752.30M | 406.90M | EBITDA |
729.50M | 743.80M | 844.10M | 887.90M | 895.20M | 531.70M | Net Income Common Stockholders |
467.20M | 492.70M | 593.40M | 585.90M | 661.80M | 346.20M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
601.80M | 484.60M | 853.90M | 894.30M | 762.60M | 615.50M | Total Assets |
3.60B | 3.64B | 3.83B | 3.62B | 3.31B | 2.79B | Total Debt |
306.60M | 302.30M | 309.00M | 317.90M | 325.30M | 325.70M | Net Debt |
-295.20M | -182.30M | -544.90M | -576.40M | -437.30M | -289.80M | Total Liabilities |
921.70M | 961.10M | 948.50M | 931.90M | 978.40M | 939.30M | Stockholders Equity |
2.68B | 2.68B | 2.88B | 2.68B | 2.34B | 1.85B |
Cash Flow | Free Cash Flow | ||||
306.90M | 276.40M | 414.50M | 439.40M | 330.60M | 298.10M | Operating Cash Flow |
664.60M | 653.40M | 776.50M | 724.00M | 584.00M | 472.50M | Investing Cash Flow |
-359.40M | -378.70M | -368.70M | -288.20M | -253.10M | -179.50M | Financing Cash Flow |
-498.60M | -622.60M | -459.60M | -293.60M | -168.10M | -137.10M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $10.44B | 28.71 | 15.15% | 1.12% | 0.34% | 17.27% | |
70 Outperform | $15.61B | 34.02 | 17.42% | 0.38% | -1.14% | -16.35% | |
66 Neutral | $12.58B | 23.83 | 11.77% | ― | 1.66% | 21.95% | |
58 Neutral | $8.41B | 116.65 | -23.93% | ― | -0.12% | -713.82% | |
56 Neutral | $16.25B | 136.07 | -8.96% | 2.90% | -20.17% | -138.32% | |
56 Neutral | $7.09B | ― | -1.16% | ― | 4.88% | -196.93% | |
52 Neutral | $5.19B | 3.04 | -44.64% | 2.82% | 16.45% | -0.53% |
West Pharmaceutical Services held its 2025 Annual Meeting of Shareholders virtually on May 6, 2025, where shareholders voted on five proposals. The proposals included the election of directors, approval of executive compensation, amendments to the Articles of Incorporation and the 2016 Omnibus Incentive Compensation Plan, and the ratification of PricewaterhouseCoopers LLP as the accounting firm for 2025. Significant shareholder participation was noted, with 89.93% of common shares represented at the meeting.
Spark’s Take on WST Stock
According to Spark, TipRanks’ AI Analyst, WST is a Outperform.
West Pharmaceutical Services scores well due to its strong financial health and positive earnings guidance. However, technical indicators suggest bearish momentum, and the valuation metrics indicate potential overvaluation. Earnings call insights reveal both strategic successes and challenges, contributing to a balanced but cautiously optimistic outlook.
To see Spark’s full report on WST stock, click here.
On April 24, 2025, West Pharmaceutical Services announced its first-quarter 2025 financial results, reporting net sales of $698.0 million, a slight increase from the previous year. The company also raised its full-year 2025 net sales and adjusted-diluted EPS guidance, reflecting confidence in its operational performance and market positioning. Despite a decline in reported-diluted EPS, the company’s strategic focus on high-value products and self-injection devices has driven growth in the Proprietary Products Segment. Additionally, West Pharmaceutical declared a third-quarter 2025 dividend, indicating a positive outlook for stakeholders.
Spark’s Take on WST Stock
According to Spark, TipRanks’ AI Analyst, WST is a Neutral.
West Pharmaceutical Services exhibits a solid financial foundation with strong profitability and a debt-free balance sheet. However, the current technical indicators suggest bearish momentum, and valuation metrics indicate potential overvaluation. The earnings call highlighted both strategic successes and significant challenges in product revenues and margins. Overall, the stock reflects moderate risk and potential for improvement with ongoing strategic initiatives.
To see Spark’s full report on WST stock, click here.
West Pharmaceutical Services announced significant leadership changes as part of its succession planning. Bernard Birkett, the Senior Vice President and Chief Financial Officer, will retire later in 2025, with a search for his successor already underway. Shane Campbell has been appointed as the Senior Vice President, Chief Proprietary Segment Officer, effective May 5, 2025, bringing extensive global management experience to the role. These changes are expected to support West’s strategic goals and long-term growth.
Spark’s Take on WST Stock
According to Spark, TipRanks’ AI Analyst, WST is a Neutral.
West Pharmaceutical Services exhibits a solid financial foundation with strong profitability and a debt-free balance sheet. However, the current technical indicators suggest bearish momentum, and valuation metrics indicate potential overvaluation. The earnings call highlighted both strategic successes and significant challenges in product revenues and margins. Overall, the stock reflects moderate risk and potential for improvement with ongoing strategic initiatives.
To see Spark’s full report on WST stock, click here.
On March 7, 2025, West Pharmaceutical Services announced the departure of Cindy Reiss-Clark, former Senior Vice President and Chief Commercial Officer. As part of her severance, she will receive salary continuation, welfare benefits, a pro-rated incentive payment, and outplacement services, in exchange for releasing claims against the company and adhering to noncompetition and nonsolicitation covenants.
Spark’s Take on WST Stock
According to Spark, TipRanks’ AI Analyst, WST is a Neutral.
West Pharmaceutical Services has a solid financial foundation with strong profitability and a debt-free balance sheet, though revenue and cash flow challenges persist. Technical indicators suggest bearish momentum, while valuation metrics indicate a potentially high valuation. Despite some challenges, the company’s strategic direction and positive guidance provide optimism for future growth.
To see Spark’s full report on WST stock, click here.
On March 7, 2025, West Pharmaceutical Services announced the departure of Cindy Reiss-Clark, Senior Vice President and Chief Commercial Officer, effective immediately. Her responsibilities will be temporarily managed by Aileen Kinsella, indicating a transitional phase in the company’s leadership structure.